Eliyahu Sharon Kalif is CFO & VP at TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA). They have made 2 open-market trades across 1 company since 2022, most recently 2026-06-11.
CIK 0001798443
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| TEVA | 65,621 | $2.7M |
Shares reported on the most recent Form 4, priced at the 2026-06-16 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TEVA | SELL · 10b5-1 | 2026-06-11 | 2026-06-16 | $34.10 | $3.6M | +2.0% | -1.3% | +17.3% |
| TEVA | SELL · 10b5-1 | 2026-05-14 | 2026-05-18 | $35.61 | $5.5M | +3.0% | -4.9% | +6.6% |
| TEVA | SELL · 10b5-1 | 2026-02-26 | 2026-03-02 | $33.64 | $11.6M | -10.8% | -7.9% | +5.5% |
| TEVA | SELL · 10b5-1 | 2025-06-12 | 2025-06-16 | $17.08 | $1.9M | -3.7% | -8.0% | +8.5% |
| TEVA | SELL · 10b5-1 | 2025-02-28 | 2025-03-04 | $16.21 | $1.8M | +4.1% | -5.4% | +10.0% |
| TEVA | SELL · 10b5-1 | 2024-03-06 | 2024-03-07 | $13.52 | $1.0M | -2.5% | +3.7% | +23.3% |
| TEVA | SELL | 2023-08-07 | 2023-08-09 | $9.73 | $684K | -1.3% | -1.2% | -7.2% |
| TEVA | SELL | 2022-08-22 | 2022-08-24 | $10.07 | $559K | -12.7% | -21.1% | -10.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.